Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention.
Review published in The American journal of cardiology (2012)
Abstract
With femoral access, bivalirudin decreases risks of major bleeding after percutaneous coronary intervention (PCI) and provides better net clinical benefit compared to unfractionated heparin (UFH) plus planned glycoprotein IIb/IIIa inhibitors. Whether this benefit exists compared to UFH monotherapy is less clear. We performed a systematic review and meta-analysis to compare outcomes in patients undergoing transfemoral PCI with UFH or bivalirudin. Randomized trials (n = 3) and observational studies (n = 13) comparing bivalirudin to UFH monotherapy were reviewed. Primary outcomes were 30-day rates of major adverse cardiovascular events (MACEs) including death, myocardial infarction (MI), urgent revascularization, as well as all-cause mortality, MI, major bleeding, and blood transfusion. We collected data from 16 studies involving 32,492 patients undergoing PCI. Most observational studies were performed in the United States, whereas all randomized trials were done in Europe. Compared to UFH monotherapy, bivalirudin was associated with similar risk of MACEs (odds ratios [OR] 0.92, 95% confidence interval [CI] 0.75 to 1.12), a substantial 45% relative decrease in major bleeding (OR 0.55, 95% CI 0.43 to 0.72), and a trend in the decrease of transfusion (OR 0.87, 95% CI 0.70 to 1.08). A decrease in mortality was seen in observational studies (OR 0.62, 95% CI 0.45 to 0.85) but remained inconclusive in randomized trials (OR 0.63, 95% CI 0.20 to 2.01). MI rate was similar with the 2 anticoagulants. In conclusion, in patients undergoing transfemoral PCI, the benefit of bivalirudin over UFH monotherapy is driven by a significant decrease in major bleeding with similar rates of MACE. As PCI practice moves toward other bleeding-avoidance strategies such as the radial approach, future studies should focus on the interaction between anticoagulant strategy and access-site choice.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
With femoral access, bivalirudin decreases risks of major bleeding after percutaneous coronary intervention (PCI) and provides better net clinical benefit compared to unfractionated heparin (UFH) plus planned glycoprotein IIb/IIIa inhibitors. Whether this benefit exists compared to UFH monotherapy is less clear.
Why This Matters for Hirudotherapy
This meta-analysis of 16 studies (3 randomized, 13 observational; 32,492 patients) compared bivalirudin with unfractionated heparin monotherapy during transfemoral percutaneous coronary intervention, reporting similar 30-day MACE but a substantial 45% relative reduction in major bleeding with bivalirudin. Bivalirudin is a synthetic direct thrombin inhibitor modeled on hirudin, the signature anticoagulant of the medicinal leech secretome, so this large evidence base directly illustrates how a leech-derived pharmacological concept performs at scale in modern interventional cardiology. The bleeding-sparing signal—without apparent ischemic compromise—helps explain why hirudin-based anticoagulation has remained influential far beyond live leech therapy. An honest caveat is that most contributing data are observational and U.S.-based, the mortality reduction was inconclusive in the randomized trials (OR 0.63, 95% CI 0.20–2.01), and the authors caution the advantage may attenuate as radial access and other bleeding-avoidance strategies displace femoral PCI.
Citation
Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention.
Bertrand et al. · The American journal of cardiology, 2012
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026